Affimed N.V.
AFMD
$0.5801
-$0.0519-8.21%
Weiss Ratings | AFMD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Rating | ||||
Reward Index | Very Weak | |||
Risk Index | Very Weak | |||
Risk Grade | E+ | |||
Reward Grade | E | |||
Rating Factors | AFMD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Dividend Index | -- | |||
Growth Index | Weak | |||
Efficiency Index | Very Weak | |||
Solvency Index | Good | |||
Total Return Index | Very Weak | |||
Volatility Index | Very Weak | |||
Beta / Standard Deviation | AFMD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Beta | 1.69 | |||
Price History | AFMD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
7-Day Total Return | -29.98% | |||
30-Day Total Return | -44.22% | |||
60-Day Total Return | -56.05% | |||
90-Day Total Return | -78.03% | |||
Year to Date Total Return | -57.03% | |||
1-Year Total Return | -91.14% | |||
2-Year Total Return | -92.15% | |||
3-Year Total Return | -98.81% | |||
5-Year Total Return | -96.82% | |||
52-Week High % Change | -92.94% | |||
52-Week Low % Change | 0.32% | |||
Price | AFMD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
52-Week High Price | $8.95 | |||
52-Week Low Price | $0.63 | |||
52-Week Low Price (Date) | Apr 03, 2025 | |||
52-Week High Price (Date) | Jun 12, 2024 | |||
Valuation | AFMD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Market Cap | 10.36M | |||
Enterprise Value | -2.14M | |||
Price/Earnings (TTM) | -- | |||
Earnings Per Share (TTM) | -4.95 | |||
Earnings Per Share Growth | -41.77% | |||
Price/Earnings To Growth | -- | |||
Price/Sales (TTM) | 1.68 | |||
Price/Book (Q) | 0.54 | |||
Enterprise Value/Revenue (TTM) | -0.35 | |||
Price | $0.58 | |||
Enterprise Value/EBITDA (TTM) | 0.03 | |||
Enterprise Value/EBIT | 0.03 | |||
Market Cap Category | Nano Cap | |||
Dividends and Shares | AFMD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Shares Outstanding | 16.10M | |||
Dividend Yield | -- | |||
Div. Per Share (Most Recent) | -- | |||
Dividend Per Share (TTM) | -- | |||
Payout Ratio (TTM) | -- | |||
Dividend Per Share (Most Recent) | -- | |||
Company Info | AFMD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Phone Number | 49 621 560030 | |||
Address | -- | |||
Website | www.affimed.com | |||
Country | Germany | |||
Year Founded | 2000 | |||
Profitability | AFMD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Operating Margin (TTM) | -1,151.93% | |||
Profit Margin | -1,248.37% | |||
Management Effectiveness | AFMD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Return on Assets | -50.84% | |||
Return on Equity | -- | |||
Income Statement | AFMD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Revenue (TTM) | 949.10K | |||
Total Revenue (TTM) | 6.08M | |||
Revenue Per Share | $0.38 | |||
Gross Profit (TTM) | 6.08M | |||
EBITDA (TTM) | -66.52M | |||
EBIT (TTM) | -69.98M | |||
Net Income (TTM) | -75.84M | |||
Net Income Avl. to Common (TTM) | -75.84M | |||
Total Revenue Growth (Q YOY) | -91.53% | |||
Earnings Growth (Q YOY) | 37.21% | |||
EPS Diluted (TTM) | -4.95 | |||
EPS Diluted Growth (Q YOY) | 41.77% | |||
Balance Sheet | AFMD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Cash and Short-Term Inv. (Q) | 26.88M | |||
Cash Per Share (Q) | $1.67 | |||
Total Current Assets (Q) | 36.13M | |||
Total Preferred Equity (Q) | -- | |||
Total Equity (Q) | 19.18M | |||
Current Ratio (Q) | 1.931 | |||
Book Value Per Share (Q) | $1.17 | |||
Total Assets (Q) | 44.57M | |||
Total Current Liabilities (Q) | 18.71M | |||
Total Debt (Q) | 14.38M | |||
Total Liabilities (Q) | 25.39M | |||
Total Common Equity (Q) | 19.18M | |||
Cash Flow | AFMD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Cash from Investing (TTM) | 21.34M | |||
Cash from Financing (TTM) | 794.20K | |||
Net Change in Cash (TTM) | -59.95M | |||
Levered Free Cash Flow (TTM) | -49.51M | |||
Cash from Operations (TTM) | -83.26M | |||